Let’s Talk Nutrition With Nico: A Black Cumin Seed Oil Beat Melatonin on Sleep, With One Big Asterisk

In the ninth episode of Let's Talk Nutrition With Nico, Lana Pine, senior editor of The Educated Patient, and Nicholas Saraceno, senior editor of Nutritional Outlook, examined two supplement launches released about a week apart: an NMN gummy and a head-to-head sleep trial comparing a botanical ingredient with synthetic melatonin. Saraceno framed both as part of the same broader trend, consumers optimizing aging, energy and recovery, and willing to try newer ingredients if the story behind them is compelling.

NMN’s regulatory reversal, explained

Saraceno pointed to Piping Rock’s new Vital NMN Gummies, launched under its Vitafusion brand at 300 milligrams per serving and marketed around healthy aging and cellular health. What made the launch notable, he said, wasn’t the marketing but the regulatory path behind it. In October 2022, the U.S. Food and Drug Administration (FDA) excluded NMN (nicotinamide mononucleotide) from the legal definition of a dietary supplement because a company had already studied it as a drug candidate, invoking the drug preclusion clause. That left NMN in a gray area for roughly two years until the FDA reconsidered citizen petitions and, by late 2025, began acknowledging new dietary ingredient notifications for it.

Saraceno was clear that this reversal settled a legal question, not a scientific one. The FDA explicitly stated that accepting a notification is a procedural step, not a safety determination. A separate 2026 meta-analysis in Nutrients, pooling 15 randomized trials with a safety-focused subset of 10 trials and 383 participants across doses of 250 to 2,000 milligrams daily for up to 24 weeks, found no increase in adverse events and no significant effect on liver enzymes. But the same review found no significant effects on body weight, fasting glucose or lipid profiles, and only a modest, nonsignificant trend on insulin resistance. Saraceno’s takeaway: NMN appears reasonably safe in the short term but hasn’t been shown to deliver the metabolic benefits that “cellular health” marketing language tends to suggest.

A rare head-to-head sleep trial

The second launch Saraceno covered was a randomized, double-blind, active-controlled crossover trial from Akay Bioactives testing its ingredient ThymoDream, a standardized black cumin seed oil, directly against 5 milligrams of synthetic melatonin. The trial included 24 adults with self-reported sleep disturbances over seven nights per arm and was published in Frontiers in Sleep.

Results showed plasma melatonin rising two to three times above baseline for up to six hours under ThymoDream, suggesting the ingredient works by boosting the body’s own melatonin production rather than supplying it directly. Sleep efficiency improved by 12.6% and total sleep time rose 8.1%, both significantly more than the melatonin arm. Cortisol dropped more than 21% under ThymoDream with no significant change under melatonin, and among participants with elevated daytime sleepiness, Epworth Sleepiness Scale scores fell by about 25% versus a nonsignificant change with melatonin.

Where the results get more complicated

Saraceno flagged several caveats. Melatonin still outperformed ThymoDream on sleep latency, meaning it got people to fall asleep faster, so “comparable to melatonin” holds on some measures but not all. The trial was also small and company-sponsored, with 24 healthy adults rather than a diagnosed insomnia population, meaning independent replication is needed before drawing firm conclusions.

He also noted that melatonin itself is a shakier comparison point than many assume. A 2022 review in Sleep Medicine Reviews, covering 24 randomized controlled trials, concluded melatonin didn’t appear effective for chronic insomnia in adults without an underlying sleep disorder, with clearer benefit mainly in children, adolescents or insomnia linked to another condition.

The throughline

Saraceno closed by distinguishing three separate questions that often get blurred in supplement marketing: regulatory clearance, ingredient novelty and clinical trial data. NMN being legal to sell doesn’t mean it performs as implied. ThymoDream outperforming melatonin on some measures doesn’t mean it wins on all of them, especially against a benchmark with its own mixed record. His advice: Manufacturers should be precise about which claim their data actually supports, and consumers should look past phrases like “clinically studied” or “FDA cleared” to ask exactly what was studied and cleared.